Companies ›Healthcare ›OPK.O

OPK.O — NASDAQ Pharmaceutical Services

OPKO Health Inc

$1,20

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-34,5 %

ROE

-17,8 %

Net margin

-37,2 %

Debt / equity

0,28

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$1,17

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

OPKO Health Inc is a diversified healthcare company focused on the development, manufacturing, and commercialization of pharmaceutical products, primarily in the areas of women's health, endocrinology, and diagnostics.

Business. OPKO Health Inc (OPK.O) is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on pharmaceuticals. The firm generates revenue through a service-based model and is headquartered in the United States. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceutical Services

Generated · model-assisted

Sell-side consensus

BUY6 analysts

4 buy2 hold0 sell

Avg 12m price target4,38

Analyst recommendations

6 analysts · consensus Buy

Buy4

Hold2

Sell0

12-month price target

4,38

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

6 analysts · indicative

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability→

-17,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning OPK.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to OPK.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

OPKO Health Inc (OPK.O) is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on pharmaceuticals. The firm generates revenue through a service-based model and is headquartered in the United States. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceutical Services

AI synthesis

GENERATED

OPKO Health Inc has a liquidity position that appears stable, with a current ratio of 3.97, indicating the company can cover its short-term liabilities more than three times over. However, the company reported negative operating cash flow of -$178.54 million and free cash flow of -$146.30 million, suggesting ongoing cash burn despite holding $364.41 million in cash and equivalents.

Profitability metrics are weak, with a return on equity of -17.8% and a return on assets of -11.68%, both significantly below the industry median for healthcare firms. The company reported a net loss of $225.68 million and an operating loss of $209.11 million, indicating a challenging operating environment.

Geographically and segment-wise, OPKO Health Inc's revenue concentration is not disclosed in the available data. However, the company operates in a highly competitive and regulated industry, with exposure to pharmaceuticals, diagnostics, and healthcare services. The lack of segment-specific revenue breakdowns limits visibility into the performance of individual business lines.

Looking ahead, the company is expected to face continued financial pressure, with no clear signs of improvement in the near term. The operating loss and negative cash flows suggest a need for strategic adjustments or external financing to sustain operations. Analysts have assigned a mean price target of $3.78, with a median of $3.00, reflecting a cautious outlook.

Risk factors include liquidity constraints and the potential for dilution, although the risk of dilution is currently assessed as low. The company has not issued any recent warnings or flags related to liquidity or dilution, but the negative operating cash flow and free cash flow could signal underlying financial stress.

Recent events include the continued focus on cost management and operational efficiency, as well as the pursuit of strategic partnerships and product development. The company has not disclosed any major new product launches or regulatory approvals in the latest filings, but it remains active in the development of new therapies and diagnostic tools.

Key takeaways

OPKO Health Inc is experiencing significant financial losses, with a net loss of $225.68 million and an operating loss of $209.11 million.
The company's liquidity position is stable, with a current ratio of 3.97, but it is burning cash at a rate of $178.54 million in operating cash flow.
Profitability metrics are weak, with a return on equity of -17.8% and a return on assets of -11.68%.
Analysts have a cautious outlook, with a mean price target of $3.78 and a median of $3.00.
The company faces ongoing financial pressure and may need to pursue strategic adjustments or external financing to sustain operations.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,20

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$1.27B

Net cashⓘ

$15.4M

Current ratioⓘ

4.0

Debt / equityⓘ

0.3

ROAⓘ

-11.7%

ROEⓘ

-17.8%

Cash conversionⓘ

79.0%

CapEx / revenueⓘ

-2.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships14 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries14

EX21:0caaa027f45aEX21:0caaa027f45aSubsidiarie97%

EX21:0fad9e31aa8cEX21:0fad9e31aa8cSubsidiarie97%

EX21:11ab5e8bca59EX21:11ab5e8bca59Subsidiarie97%

EX21:41699e2aee2dEX21:41699e2aee2dSubsidiarie97%

EX21:6832d5adacc6EX21:6832d5adacc6Subsidiarie97%

EX21:6fee76a3900fEX21:6fee76a3900fSubsidiarie97%

EX21:73386a2c983fEX21:73386a2c983fSubsidiarie97%

EX21:9e4b194ac1d3EX21:9e4b194ac1d3Subsidiarie97%

EX21:ad12ccbfb661EX21:ad12ccbfb661Subsidiarie97%

EX21:b785867e5ceeEX21:b785867e5ceeSubsidiarie97%

EX21:d01f753e3dabEX21:d01f753e3dabSubsidiarie97%

EX21:d6441fb6e1caEX21:d6441fb6e1caSubsidiarie97%

EX21:dd1ae7a1a58aEX21:dd1ae7a1a58aSubsidiarie97%

EX21:e05f726b8189EX21:e05f726b8189Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs OPK · multiples and returns

PHG—

PHG.BK

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EHC—

Encompass Health Corp

$112,47

11,5B USD

P/E

18,6x

— vs self

Div yield

0,6 %

— vs self

ROE

23,2 %

+41,9 vs self

BKD—

Brookdale Senior Living Inc

$14,37

3,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

469,6 %

+488,4 vs self

TDOC—

TELADOC HEALTH, INC.

$6,57

1,2B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-14,5 %

+4,3 vs self

HIMS—

Hims & Hers Health Inc

$25,20

5,8B USD

P/E

48,1x

— vs self

Div yield

—

— vs self

ROE

23,7 %

+42,5 vs self

NTRA—

NATERA, INC.

$270,36

38,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-8,5 %

+10,2 vs self

NHC—

National Healthcare Corp

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

PNTG—

Pennant Group Inc

$40,18

1,4B USD

P/E

39,2x

— vs self

Div yield

—

— vs self

ROE

8,1 %

+26,8 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,30

Predicted surprise

+0,01

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio 0,01 · as of 2026-07-25 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,30
Revenue	—no estimate	—no estimate	534,9M USD
Operating income	—no estimate	—no estimate	-212,0M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution6 analysts

Strong buy1

Buy3

Hold2

Sell0

Strong sell0

12-month price target$4,38 · Median $3,00

Low $3,00High $8,50

Operating income · consensus-212,0M USD

EPS surprise

+1,1 %

reported vs consensus · beat

Revenue surprise

+13,5 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$3,00

Mean$4,38

Median$3,00

High$8,50

Spot$1,20

+264.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-34,5 %Bottom quartile

Net Margin-37,2 %Below median

ROE-17,8 %Bottom quartile

Capex / Rev-2,0 %Above median

D/E0,28Below median

Cash Conv0,79Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 310 000 sh7 grants6 insiders

Yu Alice Lin-TsingDirector · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $1,42grant · 2026-06-18
Lachman Prem ADirector · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $1,42grant · 2026-06-18
UPPALURI SUBBARAO VDirector · Stock Option (Right to Buy) → Common StockAcquired 80 000 @ $1,42grant · 2026-06-18
PAGANELLI JOHN ADirector · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $1,42grant · 2026-06-18
MEDEL ROGER MDDirector · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $1,42grant · 2026-06-18
PFENNIGER RICHARD C JRDirector · Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $1,42grant · 2026-06-18
UPPALURI SUBBARAO VDirector · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $1,17grant · 2026-03-18

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

OPKO Health Inc Market data — financials · 2026-05-28
OPKO Health Inc Market data — analyst estimates · 2026-05-28
OPKO Health Inc Market data — ESG · 2026-05-28

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$7M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$9M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$37M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$13M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$4M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$2M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$41M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$4M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$1M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$11M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$2M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Phillip FrostChairman of the Board, Chief Executive Officer

Insider activity

Net buying35 buys · 0 sellsnet $4,1M2 insiders · last 365d

PAGANELLI JOHN ADirector · Common StockBought 10 000 @ $1,14$11K · 2026-03-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 3 894 @ $1,32$5K · 2025-11-21
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 191 490 @ $1,33$255K · 2025-11-21
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 192 870 @ $1,33$257K · 2025-11-21
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 102 371 @ $1,30$133K · 2025-11-21
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 89 375 @ $1,32$118K · 2025-11-21
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 161 818 @ $1,33$216K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 13 664 @ $1,35$18K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 1 757 @ $1,34$2K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 119 129 @ $1,32$157K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 47 105 @ $1,32$62K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 211 948 @ $1,33$282K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 24 579 @ $1,34$33K · 2025-11-20
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 155 496 @ $1,32$205K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 36 325 @ $1,28$46K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 58 160 @ $1,28$75K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 300 @ $1,29$387 · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 21 236 @ $1,29$28K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 30 082 @ $1,30$39K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 12 993 @ $1,30$17K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 66 504 @ $1,31$87K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 198 904 @ $1,31$262K · 2025-11-19
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 1 @ $1,29$1 · 2025-11-18
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 83 556 @ $1,28$107K · 2025-11-18
FROST PHILLIP MD ET ALDirector, CEO & Chairman, 10% owner · Common StockBought 33 572 @ $1,29$43K · 2025-11-18

Short positioning

33.6Mshares short+3.2% vs prior

12.96days to cover

57.5%short of daily vol

23.6Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

OPK.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,01Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Current ratio (FY 2025-12-31): 3.97xDerived (calculated)
Net margin (FY 2025-12-31): -37,187.0%Derived (calculated)
Gross margin (FY 2025-12-31): 33.9%Derived (calculated)
Return on equity (FY 2025-12-31): -17,798.7%Derived (calculated)
Return on assets (FY 2025-12-31): -11,681.5%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.52xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -14.6%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -18.9%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -275.0%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -275.0%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): -5.8%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -21.3%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -324.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 2.7%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 22.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 17.9%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -14.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -7.1%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -20.5%Derived (calculated)
Cash & equivalents (annual): USD 364.41MSEC XBRL filing
Cost of revenue (annual): USD 400.94MSEC XBRL filing
Operating income (annual): USD -117.41MSEC XBRL filing
Revenue (annual): USD 606.88MSEC XBRL filing

Showing 24 of 57 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-27 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-27EVENTQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-18 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative

2026-06-18FILING8-K filing →

2026-06-18INSIDERUPPALURI SUBBARAO V acquired 80.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERLachman Prem A acquired 30.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERPFENNIGER RICHARD C JR acquired 60.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERMEDEL ROGER MD acquired 30.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERPAGANELLI JOHN A acquired 30.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERYu Alice Lin-Tsing acquired 30.0k sh Stock Option (Right to Buy) — Director

2026-04-30FILINGDEF 14A filing →

2026-04-28FILING10-Q filing →

2026-04-28FILING8-K filing →

2026-03-20 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative

2026-03-20INSIDERPAGANELLI JOHN A bought 10.0k sh — Director ~$11k

2026-03-19FILING8-K filing →

2026-03-18INSIDERUPPALURI SUBBARAO V acquired 50.0k sh Stock Option (Right to Buy) — Director

2026-02-26FILING10-K filing →

2026-02-26FILING8-K filing →

2025-11-21 00:00 UTCINSIDER33 insider transactions — 2025-11 · net buy $3.0M

2025-11-21INSIDERFROST PHILLIP MD ET AL bought 3.9k sh — Director, CEO & Chairman, 10% owner ~$5k

2025-11-21INSIDERFROST PHILLIP MD ET AL bought 191.5k sh — Director, CEO & Chairman, 10% owner ~$255k

2025-11-21INSIDERFROST PHILLIP MD ET AL bought 192.9k sh — Director, CEO & Chairman, 10% owner ~$257k

2025-11-21INSIDERFROST PHILLIP MD ET AL bought 102.4k sh — Director, CEO & Chairman, 10% owner ~$133k

2025-11-21INSIDERFROST PHILLIP MD ET AL bought 89.4k sh — Director, CEO & Chairman, 10% owner ~$118k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 161.8k sh — Director, CEO & Chairman, 10% owner ~$216k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 13.7k sh — Director, CEO & Chairman, 10% owner ~$18k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 1.8k sh — Director, CEO & Chairman, 10% owner ~$2k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 119.1k sh — Director, CEO & Chairman, 10% owner ~$157k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 47.1k sh — Director, CEO & Chairman, 10% owner ~$62k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 211.9k sh — Director, CEO & Chairman, 10% owner ~$282k

2025-11-20INSIDERFROST PHILLIP MD ET AL bought 24.6k sh — Director, CEO & Chairman, 10% owner ~$33k

2025-11-19INSIDERFROST PHILLIP MD ET AL bought 155.5k sh — Director, CEO & Chairman, 10% owner ~$205k

Showing the 40 most recent of 60 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread